DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Hemophilia Market: Industry Analysis & Outlook (2017-2021)" report to their offering.
The growth factors of the hemophilia market include increased focus on prophylactic treatment, growing market for FVIII, increasing diagnosis rate, and increasing healthcare expenditure. Major trends of the market include development of novel hemophilia treatment, subcutaneous dosing and growing popularity of gene therapy. Further, growth prospects are hindered by high cost of therapy and consumers' reluctance in switching to new therapy options.
The report offers an in-depth analysis of the global hemophilia market. It also covers the global, as well as regional, aspect of the market. The top notch players in the market exhibit a very close competition. The report profiles Pfizer Inc., Bayer Group, Shire Plc, and Novo Nordisk.
Hemophilia is categorized on the basis of coagulation factor deficiency. Its types are hemophilia A, hemophilia B, hemophilia C and hemophilia with inhibitors. Symptoms of hemophilia include spontaneous bleeding from cuts or injuries, deep bruises, unusual bleeding after vaccinations, tightness in joints, double vision and many more. It can be treated via replacement therapy, prophylactic therapy, and on-demand therapy. In the coming years, gene therapy is expected to be the most attractive treatment option for people. Large pharmaceutical companies have entered into the race to develop gene therapy for hemophilia.
The US hemophilia market accounts for the largest market because of its strong market dynamics and greater scope of innovation in the region. The global hemophilia market growth will be driven by increased focus on prophylactic treatment, growing FVIII market, increasing diagnosis rate, and increasing healthcare expenditure.
The major trends of the market include development of novel hemophilia treatments, subcutaneous dosing, & increasing demand for recombinant versions of factor VIII & FIX Drugs. However, the market will be hindered by high cost of treatment and reluctance to switch to new therapies. Also, the competition in the market will be largely dominated by generalist firms.
- Increased Focus on Prophylactic Treatment
- Growing Market for FVIII
- Increasing Diagnosis Rate
- Increasing Healthcare Expenditure
- Development of Novel Hemophilia Treatments
- Subcutaneous Dosing
- Increasing Demand for Recombinant Versions of Factor VIII & FIX Drugs
- Popularity of Gene Therapy
- High Cost of Treatment
- Reluctance to Switch to New Therapies
- Bayer Group
- Novo Nordisk
- Pfizer Inc.
- Shire Plc
For more information about this report visit http://www.researchandmarkets.com/research/fcz32z/global_hemophilia.